Neumora Therapeutics, Inc. (NMRA) stock
NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.43−0.00 (-0.95%)
Close on Nov 13, 2026Market cap $80.59MP/E –Yield –
Earnings
Neumora Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 5, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q1 FY2026
–
EPS, Q1 FY2026
-$0.30
-$0.42 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Neumora Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 14, 2026before the open | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | – | – | -$0.30 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 30, 2026before the open | – | – | -$0.35 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | – | – | -$0.35 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025during market hours | – | – | -$0.33 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025during market hours | – | – | -$0.42 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 3, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | – | – | -$0.45 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024before the open | – | – | -$0.37 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024before the open | – | – | -$0.34 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 7, 2024before the open | – | – | -$0.71 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 1, 2023during market hours | – | – | -$1.14 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Neumora Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Neumora Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Neumora Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Update
- Results
- Results
- Update
- Update
- News
- News
- Results
- News
- News
- Results
- Results
- Results
See a number that looks wrong?